These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

476 related articles for article (PubMed ID: 35707003)

  • 1. Comprehensive Analysis Identifies PI3K/Akt Pathway Alternations as an Immune-Related Prognostic Biomarker in Colon Adenocarcinoma Patients Receiving Immune Checkpoint Inhibitor Treatment.
    Lin A; Gu T; Hu X; Zhang J; Luo P
    J Immunol Res; 2022; 2022():8179799. PubMed ID: 35707003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of Interleukin-1 Signaling Alterations of Colon Adenocarcinoma Identified Implications for Immunotherapy.
    Zhou X; Liu Y; Xiang J; Wang Y; Wang Q; Xia J; Chen Y; Bai Y
    Front Immunol; 2021; 12():665002. PubMed ID: 34367132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutations Status of Chemokine Signaling Pathway Predict Prognosis of Immune Checkpoint Inhibitors in Colon Adenocarcinoma.
    Lin A; Xu W; Luo P; Zhang J
    Front Pharmacol; 2021; 12():721181. PubMed ID: 34721019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploration of the relationship between tumor mutation burden and immune infiltrates in colon adenocarcinoma.
    Ouyang R; Li Z; Peng P; Zhang J; Liu J; Qin M; Huang J
    Int J Med Sci; 2021; 18(3):685-694. PubMed ID: 33437203
    [No Abstract]   [Full Text] [Related]  

  • 5. High expression of PI4K2A predicted poor prognosis of colon adenocarcinoma (COAD) and correlated with immunity.
    Huang X; Cao Y; Bao P; Zhu B; Cheng Z
    Cancer Med; 2023 Jan; 12(1):837-851. PubMed ID: 35634680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TNF-Alpha Pathway Alternation Predicts Survival of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
    Lin A; Zhang H; Meng H; Deng Z; Gu T; Luo P; Zhang J
    Front Immunol; 2021; 12():667875. PubMed ID: 34603277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of TTN Mutations on Immune Microenvironment and Efficacy of Immunotherapy in Lung Adenocarcinoma Patients.
    Wang Z; Wang C; Lin S; Yu X
    Front Oncol; 2021; 11():725292. PubMed ID: 34513703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Construction of a novel choline metabolism-related signature to predict prognosis, immune landscape, and chemotherapy response in colon adenocarcinoma.
    Liu C; Liu D; Wang F; Liu Y; Xie J; Xie J; Xie Y
    Front Immunol; 2022; 13():1038927. PubMed ID: 36451813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive Models for Colon Adenocarcinoma Diagnosis, Prognosis, and Immune Microenvironment Based on 2 Hypoxia-Related Genes: KDM3A and ENO3.
    Kong C; Zheng L; Fang S; Chen M; Lin G; Qiu R; Zhao Z; Chen W; Song J; Yang Y; Ji J
    Technol Cancer Res Treat; 2023; 22():15330338231195494. PubMed ID: 37650153
    [No Abstract]   [Full Text] [Related]  

  • 10. TET1 mutations as a predictive biomarker for immune checkpoint inhibitors in colon adenocarcinoma.
    Qiu T; Wang X; Du F; Hu X; Sun F; Song C; Zhao J
    World J Surg Oncol; 2022 Apr; 20(1):115. PubMed ID: 35395805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. To explore the prognostic characteristics of colon cancer based on tertiary lymphoid structure-related genes and reveal the characteristics of tumor microenvironment and drug prediction.
    Wang Z; Niu D
    Sci Rep; 2024 Jun; 14(1):13555. PubMed ID: 38867070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The mutational pattern of homologous recombination-related (HRR) genes in Chinese colon cancer and its relevance to immunotherapy responses.
    Zhou P; Wu X; Chen H; Hu Y; Zhang H; Wu L; Yang Y; Mao B; Wang H
    Aging (Albany NY); 2020 Dec; 13(2):2365-2378. PubMed ID: 33318301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Predictive Value of PAK7 Mutation for Immune Checkpoint Inhibitors Therapy in Non-Small Cell Cancer.
    Zeng H; Tong F; Bin Y; Peng L; Gao X; Xia X; Yi X; Dong X
    Front Immunol; 2022; 13():834142. PubMed ID: 35242138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Intratumor Heterogeneity-Related Signature for Predicting Prognosis, Immune Landscape, and Chemotherapy Response in Colon Adenocarcinoma.
    Liu C; Liu D; Wang F; Xie J; Liu Y; Wang H; Rong J; Xie J; Wang J; Zeng R; Zhou F; Xie Y
    Front Med (Lausanne); 2022; 9():925661. PubMed ID: 35872794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of the six-hormone secretion-related gene signature as a prognostic biomarker for colon adenocarcinoma.
    Jia X; Zhang T; Lv X; Du H; Sun Y; Guan Y
    Cancer Biomark; 2023; 38(4):523-535. PubMed ID: 38143338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel signature model based on mitochondrial-related genes for predicting survival of colon adenocarcinoma.
    Gao H; Xing F
    BMC Med Inform Decis Mak; 2022 Oct; 22(1):277. PubMed ID: 36273131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification prognosis-associated immune genes in colon adenocarcinoma.
    Miao Y; Wang J; Ma X; Yang Y; Mi D
    Biosci Rep; 2020 Nov; 40(11):. PubMed ID: 33140821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fibroblast growth factor receptor family mutations as a predictive biomarker for immune checkpoint inhibitors and its correlation with tumor immune microenvironment in melanoma.
    Zhang W; Xia H; Yang R; Zhang Y; Zheng Q; Shang X; Liu N; Ma X; Wei C; Chen H; Mu X; Wang X; Liu Y
    Front Immunol; 2022; 13():1030969. PubMed ID: 36426352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognosis of Lung Adenocarcinoma Patients With NTRK3 Mutations to Immune Checkpoint Inhibitors.
    Niu Y; Lin A; Luo P; Zhu W; Wei T; Tang R; Guo L; Zhang J
    Front Pharmacol; 2020; 11():1213. PubMed ID: 32903385
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Sun Y; Li L; Yao W; Liu X; Yang Y; Ma B; Xue D
    Front Genet; 2021; 12():762160. PubMed ID: 34795697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.